Biotech company is first tenant at Oxford Science Park's Bellhouse Building
Biotech company Enara Bio, is moving into the new Bellhouse Building at The Oxford Science Park.
The company is moving from the Oxford BioEscalator to one of the UK’s largest biomedical innovation centres in preparation for its future growth and ambition to transform cancer care. The dedicated research facility will enable the company to accelerate the preclinical development of its lead MR1-targeting T-cell therapy program while continuing to drive the discovery of novel cancer antigens and TCRs for immunotherapy.
The company will occupy more than 5,000 sq ft of office and laboratory space in the Bellhouse Building and will enable it to bring together key personnel with world-leading capabilities in bioinformatics, immunopeptidomics, cell therapy process development and immunology to discover and develop novel TCR-based immunotherapies.
Kevin Pojasek, President and CEO of Enara Bio, said: “We are delighted to be expanding and moving into The Oxford Science Park. As pioneers of TCR-directed T-cell immunotherapies, it seems fitting that we will be the first occupier of the Bellhouse Building, the park’s latest facility. Our current growth is fuelled by the interest generated by our innovation platform and its transformative potential. The move will enable us to scale up our research and development efforts and hopefully realise this potential as we explore novel targets such as Dark Antigens™ and MR1, which hold great promise in the search for next generation cancer immunotherapies.”
Piers Scrimshaw-Wright, CEO of The Oxford Science Park, added: “Enara Bio’s exciting work on novel immunotherapies makes it the ideal first occupier of the Bellhouse Building, named after one of the University of Oxford’s earliest entrepreneurs. Professor Brian Bellhouse formed PowderJect in 1993, and based the company at The Oxford Science Park, where Enara Bio can now continue its own pioneering research."
Enara Bio is backed by leading life science investors, including SV Health Investors and has partnerships with world-class academic institutions, including the Francis Crick Institute, Cardiff University, Johns Hopkins School of Medicine and the University of Oxford.
